India’s Glenmark Confirms Abbott Sued It Over Tarka Generic (India)
This article was originally published in PharmAsia News
Executive SummaryIndia's Glenmark Pharmaceuticals confirms Abbott Laboratories has sued it in the United States to block its FDA application for a generic version of Tarka (trandolapril, verapamil hydrochloride) for treating hypertension. Glenmark believes it was the first to file for a generic, the first for the company, but Abbott said the application violates its patent. Tarka has generated $100 million in U.S. sales for Abbott. (Click here for more ) "Glenmark Confirms Abbott Suit Against Tarka Generic" Economic Times (India) (12/13/07)
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.
Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.